Filtered By:
Specialty: Urology & Nephrology
This page shows you your search results in order of date. This is page number 15.
Order by Relevance | Date
Total 98151 results found since Jan 2013.
Patient-reported outcome measures compared to clinician reported outcomes regarding incontinence and erectile dysfunction in localized prostate carcinoma after robot assisted radical prostatectomy: Impact on management
CONCLUSIONS: This is to our knowledge the first study that compared the PROs with clinician reported functional outcomes and the impact of discrepancies on the management of side effects of RARP in prostate cancer. Observed discrepancies between the PROs and CROs did not affect offered management and counseling of UI and ED.PMID:37690935 | DOI:10.1016/j.urolonc.2023.08.001
Source: Urologic Oncology - September 10, 2023 Category: Urology & Nephrology Authors: C N Tillier A H Boekhout H Veerman B M Wollersheim Pam Groen H G van der Poel L V van de Poll-Franse Source Type: research
The prognostic value of expressions of STAT3, PD-L1, and PD-L2 in Ta/T1 urothelial carcinoma before and after BCG treatment
CONCLUSIONS: The success of BCG treatment in NMIBC was not related to PD-L1, PD-L2, and STAT3 expression status, but PD-L1 expression was correlated with both PD-L2 and STAT3 as well as TILs rate, but this correlation was lost after BCG treatment.PMID:37690934 | DOI:10.1016/j.urolonc.2023.08.012
Source: Urologic Oncology - September 10, 2023 Category: Urology & Nephrology Authors: Aziz Hakk ı Civriz Kerem Teke Enes Malik Akdas Ozdal Dillioglugil Cigdem Vural Busra Yaprak Bayrak Source Type: research
Sequential intravesical gemcitabine/docetaxel provides a durable remission in recurrent high-risk NMIBC following BCG therapy
CONCLUSIONS: In patients with recurrence after BCG therapy, sequential intravesical gem/doce is an effective and well-tolerated alternative to early cystectomy. Patients with BCG relapsing disease are more likely to respond to additional intravesical gem/doce. Further investigation with a prospective trial is imperative.PMID:37690933 | DOI:10.1016/j.urolonc.2023.06.018
Source: Urologic Oncology - September 10, 2023 Category: Urology & Nephrology Authors: Kendrick Yim Kevin Melnick Sarah L Mott Filipe L F Carvalho Affan Zafar Timothy N Clinton Matthew Mossanen Graeme S Steele Michelle Hirsch Natalie Rizzo Chin-Lee Wu Kent W Mouw Matthew Wszolek Keyan Salari Adam Feldman Adam S Kibel Michael A O'Donnell Mar Source Type: research
Patient-reported outcome measures compared to clinician reported outcomes regarding incontinence and erectile dysfunction in localized prostate carcinoma after robot assisted radical prostatectomy: Impact on management
CONCLUSIONS: This is to our knowledge the first study that compared the PROs with clinician reported functional outcomes and the impact of discrepancies on the management of side effects of RARP in prostate cancer. Observed discrepancies between the PROs and CROs did not affect offered management and counseling of UI and ED.PMID:37690935 | DOI:10.1016/j.urolonc.2023.08.001
Source: Urologic Oncology - September 10, 2023 Category: Urology & Nephrology Authors: C N Tillier A H Boekhout H Veerman B M Wollersheim Pam Groen H G van der Poel L V van de Poll-Franse Source Type: research
The prognostic value of expressions of STAT3, PD-L1, and PD-L2 in Ta/T1 urothelial carcinoma before and after BCG treatment
CONCLUSIONS: The success of BCG treatment in NMIBC was not related to PD-L1, PD-L2, and STAT3 expression status, but PD-L1 expression was correlated with both PD-L2 and STAT3 as well as TILs rate, but this correlation was lost after BCG treatment.PMID:37690934 | DOI:10.1016/j.urolonc.2023.08.012
Source: Urologic Oncology - September 10, 2023 Category: Urology & Nephrology Authors: Aziz Hakk ı Civriz Kerem Teke Enes Malik Akdas Ozdal Dillioglugil Cigdem Vural Busra Yaprak Bayrak Source Type: research
Patient-reported outcome measures compared to clinician reported outcomes regarding incontinence and erectile dysfunction in localized prostate carcinoma after robot assisted radical prostatectomy: Impact on management
CONCLUSIONS: This is to our knowledge the first study that compared the PROs with clinician reported functional outcomes and the impact of discrepancies on the management of side effects of RARP in prostate cancer. Observed discrepancies between the PROs and CROs did not affect offered management and counseling of UI and ED.PMID:37690935 | DOI:10.1016/j.urolonc.2023.08.001
Source: Urologic Oncology - September 10, 2023 Category: Urology & Nephrology Authors: C N Tillier A H Boekhout H Veerman B M Wollersheim Pam Groen H G van der Poel L V van de Poll-Franse Source Type: research
Sequential intravesical gemcitabine/docetaxel provides a durable remission in recurrent high-risk NMIBC following BCG therapy
CONCLUSIONS: In patients with recurrence after BCG therapy, sequential intravesical gem/doce is an effective and well-tolerated alternative to early cystectomy. Patients with BCG relapsing disease are more likely to respond to additional intravesical gem/doce. Further investigation with a prospective trial is imperative.PMID:37690933 | DOI:10.1016/j.urolonc.2023.06.018
Source: Urologic Oncology - September 10, 2023 Category: Urology & Nephrology Authors: Kendrick Yim Kevin Melnick Sarah L Mott Filipe L F Carvalho Affan Zafar Timothy N Clinton Matthew Mossanen Graeme S Steele Michelle Hirsch Natalie Rizzo Chin-Lee Wu Kent W Mouw Matthew Wszolek Keyan Salari Adam Feldman Adam S Kibel Michael A O'Donnell Mar Source Type: research
The prognostic value of expressions of STAT3, PD-L1, and PD-L2 in Ta/T1 urothelial carcinoma before and after BCG treatment
CONCLUSIONS: The success of BCG treatment in NMIBC was not related to PD-L1, PD-L2, and STAT3 expression status, but PD-L1 expression was correlated with both PD-L2 and STAT3 as well as TILs rate, but this correlation was lost after BCG treatment.PMID:37690934 | DOI:10.1016/j.urolonc.2023.08.012
Source: Urologic Oncology - September 10, 2023 Category: Urology & Nephrology Authors: Aziz Hakk ı Civriz Kerem Teke Enes Malik Akdas Ozdal Dillioglugil Cigdem Vural Busra Yaprak Bayrak Source Type: research
Sequential intravesical gemcitabine/docetaxel provides a durable remission in recurrent high-risk NMIBC following BCG therapy
CONCLUSIONS: In patients with recurrence after BCG therapy, sequential intravesical gem/doce is an effective and well-tolerated alternative to early cystectomy. Patients with BCG relapsing disease are more likely to respond to additional intravesical gem/doce. Further investigation with a prospective trial is imperative.PMID:37690933 | DOI:10.1016/j.urolonc.2023.06.018
Source: Urologic Oncology - September 10, 2023 Category: Urology & Nephrology Authors: Kendrick Yim Kevin Melnick Sarah L Mott Filipe L F Carvalho Affan Zafar Timothy N Clinton Matthew Mossanen Graeme S Steele Michelle Hirsch Natalie Rizzo Chin-Lee Wu Kent W Mouw Matthew Wszolek Keyan Salari Adam Feldman Adam S Kibel Michael A O'Donnell Mar Source Type: research
Is day-case surgery feasible for laser endoscopic enucleation of the prostate? A systematic review
ConclusionLaser EEP is feasible and promising DCS treatment option delivering improved functional parameters compared to baseline values, and lower perioperative complication and readmission rates in certain patients.
Source: World Journal of Urology - September 10, 2023 Category: Urology & Nephrology Source Type: research
Standardized, risk-adapted induction therapy in kidney transplantation
CONCLUSIONS: Our strategy offers facilitated and individualized choice of induction therapy in kidney transplantation. We propose further evaluation of our algorithm in prospective trials.PMID:37688753 | DOI:10.1007/s40620-023-01746-1
Source: Journal of Nephrology - September 9, 2023 Category: Urology & Nephrology Authors: Felix Eisinger Thomas M ühlbacher Ario Na Karina Althaus Silvio Nadalin Andreas L Birkenfeld Nils Heyne Martina Guthoff Source Type: research
Gender Disparities in Access to Kidney Transplant
Clin J Am Soc Nephrol. 2023 Sep 8. doi: 10.2215/CJN.0000000000000287. Online ahead of print.NO ABSTRACTPMID:37682563 | DOI:10.2215/CJN.0000000000000287
Source: Clinical Journal of the American Society of Nephrology : CJASN - September 8, 2023 Category: Urology & Nephrology Authors: Catherine Campbell Source Type: research
